These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12396831)

  • 41. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
    Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
    Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rejection of leukemic cells requires antigen-specific T cells with high functional avidity.
    Vincent K; Hardy MP; Trofimov A; Laumont CM; Sriranganadane D; Hadj-Mimoune S; Salem Fourati I; Soudeyns H; Thibault P; Perreault C
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):37-45. PubMed ID: 24161924
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The preparation of myeloma-specific T cells activated with dendritic cells loaded with nonapeptides derived from mucin protein MUC1 and catalytic subunit of telomerase hTERT].
    Ocadlíková D; Kovárová L; Hájek R; Michálek J
    Klin Onkol; 2008; 21(2):59-65. PubMed ID: 19102213
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Immunotherapy: new insights].
    Geissler M; Weth R
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2236-46. PubMed ID: 12564040
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Telomerase reverse transcriptase as target for anti-tumor T cell responses in humans.
    Zanetti M; Hernandez X; Langlade-Demoyen P
    Springer Semin Immunopathol; 2005 Jun; 27(1):87-104. PubMed ID: 15711953
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients.
    Siliņa K; Zayakin P; Kalniņa Z; Ivanova L; Meistere I; Endzeliņš E; Abols A; Stengrēvics A; Leja M; Ducena K; Kozirovskis V; Linē A
    J Immunother; 2011 Jan; 34(1):28-44. PubMed ID: 21150711
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.
    Gross DA; Graff-Dubois S; Opolon P; Cornet S; Alves P; Bennaceur-Griscelli A; Faure O; Guillaume P; Firat H; Chouaib S; Lemonnier FA; Davoust J; Miconnet I; Vonderheide RH; Kosmatopoulos K
    J Clin Invest; 2004 Feb; 113(3):425-33. PubMed ID: 14755339
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of optimized cryptic peptides for immunotherapy.
    Menez-Jamet J; Kosmatopoulos K
    IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoepitopes as cancer immunotherapy targets: key challenges and opportunities.
    Brennick CA; George MM; Corwin WL; Srivastava PK; Ebrahimi-Nik H
    Immunotherapy; 2017 Mar; 9(4):361-371. PubMed ID: 28303769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cancer-specific gene therapy.
    Lo HW; Day CP; Hung MC
    Adv Genet; 2005; 54():235-55. PubMed ID: 16096014
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy.
    Vonderheide RH; June CH
    Immunol Res; 2003; 27(2-3):341-56. PubMed ID: 12857980
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
    Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
    Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor antigens recognized by T lymphocytes.
    Boon T; Cerottini JC; Van den Eynde B; van der Bruggen P; Van Pel A
    Annu Rev Immunol; 1994; 12():337-65. PubMed ID: 8011285
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor neoantigens: building a framework for personalized cancer immunotherapy.
    Gubin MM; Artyomov MN; Mardis ER; Schreiber RD
    J Clin Invest; 2015 Sep; 125(9):3413-21. PubMed ID: 26258412
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of immunogenic peptides of the self-tumor antigen: our experience with telomerase reverse transcriptase.
    Cortez-Gonzalez X; Zanetti M
    Methods Mol Biol; 2010; 651():211-25. PubMed ID: 20686968
    [TBL] [Abstract][Full Text] [Related]  

  • 57. T-cell recognition of oncogene products: a new strategy for immunotherapy.
    Ioannides CG; Ioannides MG; O'Brian CA
    Mol Carcinog; 1992; 6(2):77-82. PubMed ID: 1382444
    [No Abstract]   [Full Text] [Related]  

  • 58. A survivin specific T-cell clone from a breast cancer patient display universal tumor cell lysis.
    Sørensen RB; Svane IM; Straten PT; Andersen MH
    Cancer Biol Ther; 2008 Dec; 7(12):1885-7. PubMed ID: 18927499
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Survivin' cancer.
    Emens LA
    Cancer Biol Ther; 2004 Feb; 3(2):180-3. PubMed ID: 15054305
    [No Abstract]   [Full Text] [Related]  

  • 60. Cancer immunotherapy: synthetic and natural peptides in the balance.
    Bellone M; Iezzi G; Imro MA; Protti MP
    Immunol Today; 1999 Oct; 20(10):457-62. PubMed ID: 10500293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.